首页> 外文期刊>The American heart journal >Loss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: results from the Occluded Artery Trial (OAT).
【24h】

Loss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: results from the Occluded Artery Trial (OAT).

机译:梗塞性动脉闭塞患者短期症状获益的丧失与非协议血运重建无关:闭塞性动脉试验(OAT)的结果。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: the OAT found that routine late (3-28 days post-myocardial infarction) percutaneous coronary intervention (PCI) of an occluded infarct-related artery did not reduce death, reinfarction, or heart failure relative to medical treatment (MED). Angina rates were lower in PCI early, but the advantage over MED was lost by 3 years. METHODS: angina and revascularization status were collected at 4 months, then annually. We assessed whether non-protocol revascularization procedures in MED accounted for loss of the early symptomatic advantage of PCI. RESULTS: seven per 100 more PCI patients were angina-free at 4 months (P < .001) and 5 per 100 at 12 months (P = .005) with the difference narrowing to 1 per 100 at 3 years (P = .34). Non-protocol revascularization was more frequent in MED (5-year rate 22% vs 19% PCI, P = .05). Indications for revascularization included acute coronary syndromes (39% PCI vs 38% MED), stable angina/inducible ischemia (39% in each group), and physician preference (17% PCI vs 15% MED). Revascularization rates among patients with angina at any time during follow-up (35% of cohort) did not differ by treatment group (5-year rates 26% PCI vs 28% MED). Most symptomatic patients were treated without revascularization during follow-up (77%). CONCLUSIONS: in a large randomized clinical trial of stable post-myocardial infarction patients, the modest benefit on angina from PCI of an occluded infarct-related artery was lost by 3 years. Revascularization was slightly more common in MED during follow-up but was not driven by acute ischemia, and almost 1 in 5 procedures were attributed to physician preference alone.
机译:背景:OAT发现,相对于药物治疗(MED),阻塞性梗死相关动脉的常规晚期(心肌梗塞后3-28天)经皮冠状动脉介入治疗(PCI)不能减少死亡,再梗塞或心力衰竭。 PCI早期的心绞痛发生率较低,但与MED相比,优势已丧失了3年。方法:在4个月时收集心绞痛和血运重建状况,然后每年收集一次。我们评估了MED中的非协议血运重建程序是否可解释PCI早期症状优势的丧失。结果:每100个PCI患者中有7个在4个月时无心绞痛(P <.001),在12个月时每100个患者中有5个无心绞痛(P = .005),在3年时差异缩小到每100个患者中有1个(P = .34) )。非协议血运重建在MED中更为频繁(5年率22%vs 19%PCI,P = 0.05)。血运重建的适应症包括急性冠状动脉综合征(39%PCI对38%MED),稳定型心绞痛/诱导性缺血(每组39%)和医师偏爱(17%PCI对15%MED)。随访期间,任何时候心绞痛患者的血运重建率(队列的35%)在治疗组中均无差异(5年率分别为26%PCI和28%MED)。大多数有症状患者在随访期间均接受了无血运重建的治疗(77%)。结论:在一项稳定的心肌梗死后患者的大型随机临床试验中,阻塞性梗塞相关动脉的PCI对心绞痛的适度获益在3年后消失。随访期间,在MED中血运重建略多见,但并非由急性缺血驱动,并且几乎五分之一的手术仅归因于医师偏爱。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号